title: [Strontium-89 for bone metastases from prostate cancer: an update].
abstract: Strontium-89 (Sr-89) is a pure emitter with maximum beta energy of 1.46 MeV, average beta energy of 0.58 MeV, and a physical half-life of 50.5 days. It is rapidly taken up by bone and preferentially retained at the sites of osseous metastases. Its biological half-life is >50 days at the metastatic sites, but about 14 days only in the normal bone. The dose of its absorption in the tumor-bearing bone ranges from 21 +/- 4 to 231 +/- 56 cGy/MBq, 2-25 times higher than in the normal bone. Strontium-89 therapy is an effective palliative treatment of bone metastases from prostate cancer, with analgesic effectiveness in 80%.
authors.affiliation: Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
authors.forename: Wei-wei
authors.initials: WW
authors.lastname: Zhao
authors.forename: Peng
authors.initials: P
authors.lastname: Xie
authors.forename: Hou-fu
authors.initials: HF
authors.lastname: Deng
mesh_terms: D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D013326:Strontium Radioisotopes / Q000627:therapeutic use*
chemical_list: D013326:Strontium Radioisotopes